Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported financial results for the first quarter ended March 31, 2026, revealing a significant decline in revenue and a shift to a net loss as the company executes a strategic transformation to reduce client concentration and build a more resilient business model.
Revenue for the quarter was $648,140, a 44% decrease from the same period in the prior year. The drop was driven almost entirely by a change in activities within a large project for a major customer, which had been expected to continue through 2026. Management is expanding service offerings and capabilities to generate consistent recurring revenue and mitigate such client concentration risk.
Gross profit for the quarter was $202,231, with a gross margin of 31.2%, compared to 53.6% in the prior year. Margins were negatively impacted by underutilized capacity, as the Company maintained staffing and operational readiness in anticipation of executing the planned customer work. The Company recorded a net and comprehensive loss of $401,295 for the quarter, compared to net income of $63,523 in Q1 2025. Operating expenses increased year over year, reflecting the Q1 integration of Keystone Labs and Innovotech Labs, relocating the former Keystone Labs operations to a new nearby facility, and investments in a stronger sales organization.
Innovotech continued to advance its strategic transformation, including strengthening its leadership and commercial teams, and completing its OTCQB listing in the U.S. The Company operates with a strong liquidity position and maintains a meaningful equity base, providing flexibility to manage near-term volatility while continuing to execute its longer-term strategy.
“Management remains committed to investing in a more diversified, resilient, and scalable platform,” said Innovotech CEO Craig Milne. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
For business and technology leaders, Innovotech's results highlight the risks of revenue concentration in life sciences services and the importance of diversification. The company's investments in integration, facility relocation, and sales expansion demonstrate a proactive approach to building a more stable revenue base, though near-term profitability has been sacrificed. The OTCQB listing may enhance visibility among U.S. investors, potentially supporting future capital access.
The Company’s unaudited consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) have been filed on SEDAR+ and the OTCIQ. Innovotech Inc. is a life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech operates through ISO-certified and GMP-accredited laboratories, supporting clients across multiple sectors and geographies. More information is available at https://www.innovotech.ca.
Forward-looking statements in this release are subject to risks and uncertainties, including regulatory outcomes, reliance on a small number of customers, fluctuations in operating results, and other factors detailed in the Company's filings. Actual results may differ materially.
